B+
Bull case
25%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
SVRA
SavaraCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case is that SVRA is now essentially a late-stage regulatory setup: FDA filed the BLA on February 20, 2026 with Priority Review [#PR-2026-02-20], March 6 brought a Day 74 update saying no Advisory Committee is planned [#PR-2026-03-06], and April 15 said the delay came from a major amendment without cited safety, efficacy, or manufacturing concerns [#PR-2026-04-15]. If that path ends in approval, the stock likely rerates sharply because MOLBREEVI could be the first approved therapy in autoimmune PAP and Savara has already been building commercial infrastructure.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +2.2.
What can break
Commercialization and launch-spend plans may pressure cash usage even though year-end liquidity was strong.
Momentum
21
Value
41
Sentiment
70
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.40 · Bull $9.50 · Bear $3.00Analysis 2026-04-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $10.94
Why
Momentum21 · Δ7d +5.8
Value41 · Δ7d 0.0
Sentiment70 · Δ7d +2.2
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +2.2.
Contradictions & invalidation
- • Commercialization and launch-spend plans may pressure cash usage even though year-end liquidity was strong.
- • FDA review risk remains the dominant driver after the PDUFA date moved to November 22, 2026.
- • The bear case is that this remains a concentrated single-asset thesis with weak diversification and a now-longer wait to the decisive catalyst.
Catalyst clock
2026-05-17
ATS 2026 presentations could shape sentiment ahead of the FDA decision
Lead driver: Sentiment · See AI snapshot
Momentum
21
9% active weight
Current posture
7d trendImproving
Δ7d
+5.8
Δ21d
-5.9
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
70
62% active weight
Current posture
7d trendImproving
Δ7d
+2.2
Δ21d
-1.9
Why this grade
Composite grade C. Momentum 21.1 / Value 41.2 / Sentiment 70.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-17. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$5.40
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$3.00
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1.1B
Beta
0.34
Shares Out
205.46M
P/E (TTM) · Derived
-10.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-11.75
Rev YoY
-100.0%
EPS YoY
+13.0%
Gross Margin
+93.5%
Op Margin
-
Net Debt
-$205.79M
Current Ratio
10.13
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data